Effects of saturated long-chain N-acylethanolamines on voltage-dependent Ca2+ fluxes in rabbit T-tubule membranes.
The effects of saturated long-chain (C: 16-22) N-acylethanolamines and a series of saturated fatty acids with the same length of carbon chains were investigated on depolarization-induced (45)Ca(2+) fluxes mediated by voltage-dependent Ca(2+) channels in transverse tubule membrane vesicles from rabbit skeletal muscle. Vesicles were loaded with (45)Ca(2+) and membrane potentials were generated by establishing potassium gradients across the vesicle using the ionophore valinomycin. Arachidonoylethanolamide and docosaenoylethanolamide but not palmitoylethanolamide and stearoylethanolamide (all 10 microM) caused a significant inhibition of depolarization-induced (45)Ca(2+) fluxes and specific binding of [(3)H]Isradipine to transverse tubule membranes. On the other hand, saturated fatty acids including palmitic, stearic, arachidic, and docosanoic acids (all 10 microM) were ineffective in functional and radioligand binding experiments. Additional experiments using endocannabinoid metabolites suggested that whereas ethanolamine and arachidic acids were ineffective, arachidonoylethanolamide inhibited Ca(2+) effluxes and specific binding of [(3)H]Isradipine. Further studies indicated that only those fatty acids containing ethanolamine as a head group and having a chain length of more than 18 carbons were effective in inhibiting depolarization-induced Ca(2+) effluxes and specific binding of [(3)H]Isradipine. In conclusion, results indicate that depending on the chain length and the head group of fatty acid, N-acylethanolamines have differential effects on the function of voltage-dependent Ca(2+) channels and on the specific binding of [(3)H]Isradipine in skeletal muscle membranes.
Oz
Murat
M
National Institute on Drug Abuse, Cellular Neurobiology Section, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA. moz@intra.nida.nih.gov
Alptekin
Alp
A
Tchugunova
Yulia
Y
Dinc
Meral
M
D000577:Amides; D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D015220:Calcium Channels / Q000378:metabolism*; D002244:Carbon / Q000737:chemistry; D002462:Cell Membrane / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D063388:Endocannabinoids; D004983:Ethanolamines / Q000737:chemistry*; D005227:Fatty Acids / Q000378:metabolism; D015640:Ion Channel Gating; D007476:Ionophores / Q000494:pharmacology; D017275:Isradipine / Q000378:metabolism; D007684:Kidney Tubules / Q000378:metabolism*; D008564:Membrane Potentials; D018482:Muscle, Skeletal / Q000378:metabolism; D010169:Palmitic Acids / Q000494:pharmacology; D053284:Polyunsaturated Alkamides; D011188:Potassium / Q000378:metabolism; D011485:Protein Binding; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011817:Rabbits; D013229:Stearic Acids / Q000494:pharmacology; D014634:Valinomycin / Q000494:pharmacology
D000577:Amides; D001095:Arachidonic Acids; D002121:Calcium Channel Blockers; D015220:Calcium Channels; D063388:Endocannabinoids; D004983:Ethanolamines; D005227:Fatty Acids; D007476:Ionophores; C022203:N-acylethanolamines; D010169:Palmitic Acids; D053284:Polyunsaturated Alkamides; D047428:Protein Kinase Inhibitors; D013229:Stearic Acids; C466089:stearoylethanolamide; D014634:Valinomycin; C005958:palmidrol; D002244:Carbon; D011188:Potassium; D002118:Calcium; C078814:anandamide; D017275:Isradipine